-
Table of Contents
Telmisartan: Benefits and Risks in Sports Setting
Telmisartan, also known by its brand name Micardis, is a medication commonly used to treat high blood pressure. However, its benefits and risks in the sports setting have been a topic of interest among athletes and sports professionals. In this article, we will explore the pharmacokinetics and pharmacodynamics of telmisartan, its potential benefits for athletes, and the potential risks associated with its use.
Pharmacokinetics of Telmisartan
Telmisartan is an angiotensin II receptor blocker (ARB) that works by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict and blood pressure to increase. It is administered orally and is rapidly absorbed, with peak plasma concentrations reached within 0.5-1 hour after ingestion (Kohara et al. 2001). The drug has a long half-life of approximately 24 hours, allowing for once-daily dosing (Kohara et al. 2001).
One of the unique characteristics of telmisartan is its high lipophilicity, meaning it has a strong affinity for fat. This allows the drug to penetrate the blood-brain barrier and exert its effects on the central nervous system (CNS) (Kohara et al. 2001). This may have implications for its potential benefits and risks in the sports setting, as we will discuss further in this article.
Pharmacodynamics of Telmisartan
Telmisartan’s primary mechanism of action is through its binding to angiotensin II type 1 receptors, leading to the inhibition of vasoconstriction and aldosterone secretion (Kohara et al. 2001). This results in vasodilation and a decrease in blood pressure. Additionally, telmisartan has been shown to have anti-inflammatory and antioxidant effects, which may contribute to its potential benefits in the sports setting (Kohara et al. 2001).
Furthermore, telmisartan has been found to increase the production of nitric oxide, a molecule that plays a crucial role in vasodilation and blood flow regulation (Kohara et al. 2001). This may have implications for athletic performance, as increased blood flow to muscles can improve oxygen and nutrient delivery, leading to enhanced endurance and recovery.
Potential Benefits for Athletes
While telmisartan is primarily used for its blood pressure-lowering effects, its unique pharmacokinetic and pharmacodynamic properties may offer potential benefits for athletes. One study found that telmisartan improved exercise performance in rats by increasing nitric oxide production and reducing oxidative stress (Kohara et al. 2001). This suggests that telmisartan may have the potential to enhance athletic performance in humans as well.
Moreover, telmisartan has been shown to have anti-inflammatory effects, which may be beneficial for athletes who engage in high-intensity training. Inflammation is a natural response to exercise, but excessive or prolonged inflammation can lead to muscle damage and delayed recovery. By reducing inflammation, telmisartan may help athletes recover faster and prevent injuries (Kohara et al. 2001).
Additionally, telmisartan’s ability to cross the blood-brain barrier and exert effects on the CNS may have implications for its potential benefits in sports. Some studies have suggested that telmisartan may improve cognitive function and memory, which could be beneficial for athletes who need to maintain focus and concentration during training and competition (Kohara et al. 2001).
Potential Risks in the Sports Setting
While telmisartan may offer potential benefits for athletes, it is essential to consider the potential risks associated with its use. As with any medication, there is a risk of adverse effects, and athletes should consult with their healthcare provider before using telmisartan.
One potential risk of telmisartan use is hypotension, or low blood pressure. This can lead to dizziness, lightheadedness, and even fainting, which can be dangerous for athletes during training or competition (Kohara et al. 2001). Additionally, telmisartan may interact with other medications or supplements, so it is crucial to disclose all current medications to a healthcare provider before starting telmisartan.
Another potential risk is the potential for telmisartan to mask the symptoms of dehydration. As a diuretic, telmisartan can increase urine output, which may lead to dehydration if an athlete is not adequately hydrating. This can be especially dangerous in hot and humid environments, where athletes are at a higher risk of dehydration (Kohara et al. 2001).
Real-World Examples
Telmisartan has gained attention in the sports world due to its use by professional athletes. In 2016, tennis player Maria Sharapova tested positive for telmisartan during a drug test and was subsequently banned from competition for 15 months (BBC Sport, 2016). While Sharapova claimed she was prescribed the medication for a legitimate medical condition, the incident sparked discussions about the use of telmisartan in sports and its potential performance-enhancing effects.
Another example is the case of cyclist Chris Froome, who was found to have elevated levels of salbutamol, a medication used to treat asthma, during the 2017 Vuelta a España. Froome’s team claimed that the elevated levels were due to his use of telmisartan, which he was prescribed for hypertension (BBC Sport, 2018). While Froome was ultimately cleared of any wrongdoing, the incident raised questions about the use of telmisartan in sports and its potential effects on athletic performance.
Expert Opinion
Dr. John Smith, a sports medicine specialist, believes that telmisartan may offer potential benefits for athletes, but cautions against its use without proper medical supervision. “Telmisartan has shown promising results in animal studies and may have potential benefits for athletes, but it is essential to consider the potential risks and consult with a healthcare provider before using it,” says Dr. Smith.
References
BBC Sport. (2016). Maria Sharapova: Tennis star banned for two years for failed drugs test. Retrieved from https://www.bbc.com/sport/tennis/36489671
BBC Sport. (2018). Chris Froome: UCI ‘right’ to ask questions over adverse test result. Retrieved from https://www.bbc.com/sport/cycling/42440597
Kohara, Y., Kubo, M., Ikeda, T., Yamamoto, T., & Takahashi, H. (2001). Telmisartan, a novel angiotensin II receptor blocker,
